Whether neratinib (neratinib) has been launched in Hong Kong and its market sales status

Neratinib is an oral, small-molecule tyrosine kinase inhibitor mainly used to treat HER2-positive breast cancer. The drug has been officially launched in Hong Kong and has legal sales channels in the local medical market as an original drug. Hong Kong's medical system is relatively complete, and patients can obtain neratinib through public and private medical institutions, especially private hospitals and designated pharmacies, ensuring drug quality and drug safety.

Compared with some overseas generic versions, the original drug of neratinib on the Hong Kong market is subject to strict supervision, and the quality and efficacy of the drug are fully guaranteed. Patients can avoid the possible quality differences and safety hazards of generic drugs by choosing original drugs. Especially for breast cancer patients who require long-term maintenance treatment, the use of original drugs can help stabilize the efficacy and reduce unnecessary risks.

In terms of price, the price of the original drug of neratinib in Hong Kong is relatively high and the burden on patients is heavy. However, some medical insurance or drug assistance programs in Hong Kong can help reduce the cost pressure. In contrast, neratinib has also been launched in mainland China and is included in medical insurance. The price is about 6,000 to 7,000 yuan per box. The specific price after medical insurance reimbursement varies by region. At the same time, there are also generic versions of drugs produced by Lucius and other manufacturers on the market, which cost about two to three thousand yuan, significantly reducing the cost of medication for patients.

Overall, the launch of neratinib as an original drug in Hong Kong meets patients' demand for high-quality drugs and provides an effective treatment option for local breast cancer patients. Patients can choose Hong Kong original drugs or domestic generic drugs based on their own financial situation and treatment needs. In the future, with the further development of the market and policies, the accessibility and patient support measures of neratinib in Hong Kong, Macao and Greater China are expected to continue to improve and benefit more patients.

Reference materials:https://www.drugs.com/